ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IQV / financials
INCY (88) MEDP (77) CRL (64) ICLR (72) ⌘ Pro Terminal →

IQVIA Holdings Inc. (IQV) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$258.44 -3.32% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $256.40

IQVIA Holdings Inc. (IQV) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $44.06B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IQV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, IQVIA Holdings Inc. (NYSE: IQV) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $258.44 (-3.32% 1D, market cap $44.06B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IQV ranks #154 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IQV compare to INCY and MEDP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C- (61/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A grade (88/100 RQD, P/E 18.4x, ROIC 42.4%, cap $24.54B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IQV?
▼

Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $256.40 (-0.79%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510061
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk D
Cash (13)Whales (15)SEC (10)Macro (10)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+1.4% Base Target
$309 Bull$262 Base$204 Bear
📬 FREE IQV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IQV)Realized 20D OHLCV Swing Band: ±6.9%
Deterministic 5-Pillar Attribution (61/100 Composite)
🔍 WHY IQV SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (25% of score)

20D Institutional Volume Accumulation (±6.9% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 11.8% FCF Margin ($1.92B FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (48.3) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
69
Grade B-$262.01+5.6% Next Q
Q2 (-2Q)
66
Grade B-$276.63+0.9% Next Q
Q3 (-1Q)
64
Grade C+$279.04-7.4% Next Q
Current
61
Grade C-$258.44+0.5% Hist 90D α
Trajectory: B- (69) → C- (61)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IQV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, IQV faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($266.85) or 200D SMA ($210.04) invalidates the momentum regime and cuts Target Base ($261.93) toward Bear Floor ($204.31).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IQV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IQV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 61%NO 39%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How IQV Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$1.92B (11.8% FCF Margin)
Revenue$16.31BGross Profit $8.48B (52%)Cost of Sales $7.83BOp Profit $2.18B (13.4%)OpEx (R&D/SG&A) $6.30BNet Profit$1.36B (8.3%)Tax/Other $822.0M

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $14.98B
FY24
Rev $15.40B
FY25
Rev $16.31B
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$16.31B52%13.4%$1.36B$1.92B9.4%
FY 2024$15.40B52%14.3%$1.37B$2.02B10.1%
FY 2023$14.98B52%13.2%$1.36B$1.47B10.4%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IQV)

  • ✓Walkthrough of IQV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IQV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +60.58%▼ SUPPORT BREAKDOWN
2026-11-03O $275.1H $275.1L $258.4C $258.4VOL 1.15M
RES: $334.5SUP: $271.5SMA50: $266.9SMA200: $210.0
$293.5$256.4$219.3$182.2$145.1RES $334.5SUP $271.5$258.42026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IQV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IQV Butterfly Map → + Track IQV →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.7%/yr Implied 5Y Growth

vs. +5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IQV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IQV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IQV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IQV)

Health Care Rank #154 of 1015 ⚔️ INCY vs IQV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IQV vs. INCY, MEDP, CRL, ICLR)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, IQVIA Holdings Inc. (IQV) ranks #154 by composite RQD confidence (61/100, grade C-) and #41 by equity capitalization ($44.06B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 88/100 (A) compared with IQV at 61/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IQV ACTIVE
IQVIA Holdings Inc.
C- 61/100 33.3x — 9.4% -3.32% $44.06B Benchmark Subject
INCY
Incyte Corp.
A 88/100 18.4x 92.8% 42.4% -0.29% $24.54B /incy-vs-iqv →
MEDP
Medpace Holdings Inc.
B+ 77/100 42.0x — 27.9% -0.59% $18.24B /medp-vs-iqv →
CRL
Charles River Laboratories International Inc.
C 64/100 — — 0.4% -5.81% $17.16B /crl-vs-iqv →
ICLR
ICON plc
B 72/100 71.9x — 3.1% -2.94% $16.18B /iclr-vs-iqv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001478242 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IQVIA Holdings Inc. (IQV) reported GAAP revenue of $16.31B (+5.9% vs. FY2024 revenue of $15.40B , and +8.8% cumulative change since FY2023) , GAAP net income of $1.36B, operating cash flow of $2.65B, and free cash flow of $1.92B (-5.1% YoY). On the balance sheet, IQV closed FY2025 with $29.94B in total assets against $13.88B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.31B $1.36B $2.65B $1.92B $29.94B $13.88B
FY2024 (FY) 2024-12-31 $15.40B $1.37B $2.72B $2.02B $26.90B $12.84B
FY2023 (FY) 2023-12-31 $14.98B $1.36B $2.15B $1.47B $24.93B $5.83B

3. IQV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, IQVIA Holdings Inc. (NYSE: IQV) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $258.44 (-3.32% 1D, market cap $44.06B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IQV ranks #154 in composite RQD confidence.

How does IQV compare to INCY and MEDP in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C- (61/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A grade (88/100 RQD, P/E 18.4x, ROIC 42.4%, cap $24.54B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IQV?

Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IQV trading relative to its 50-day, 200-day, and 52-week technical levels?

IQV last traded at $258.44 (-3.32% on volume of 1,369,121 shares), positioning the stock -3.15% below its 50-day simple moving average ($266.85) and +23.04% above its 200-day simple moving average ($210.04). Across its 52-week range of $154.50 to $284.50, IQV sits at the 80.0% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($240.61 to $276.27).

Direct Sub-Reports: IQV RQD Cockpit IQV 12M Forecast IQV Earnings & Move IQV Dividends & DRIP IQV Insiders & 13F IQV Whale Options IQV Profit Sankey IQV News & Why
ROARABLE RATING BRIEF • RQD 61/100 (C-) ✓ SEC XBRL & RQD VERIFIED

IQV — IQVIA Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

IQVIA Holdings Inc. (IQV) earns a live Roarable RQD composite score of 61/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $258.44 (-3.32% 1D, market capitalization $44.06B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 9.4%, gross margin of —, operating margin of 13.4%, and free cash flow yield of 4.24%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.16x equity beta, Altman Z-Score of 2.22, Piotroski F-Score of 6/9, and Debt/Equity of 2.14x.

2. Business Model, Unit Margins & SEC Financial Trajectory

IQVIA Holdings Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Commercial Physical & Biological Resarch industry..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IQVIA Holdings Inc. (IQV) reported $16.31B in annual revenue (up from $15.40B in FY2024, +5.9% YoY) and $1.36B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.98B revenue, $1.36B net income) through FY2025, IQV scaled operating cash flow to $2.65B and free cash flow to $1.92B, backed by $29.94B in total assets against $13.88B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 61/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 4.24% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $154.50 – $284.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 33.3x trailing P/E and 20.4x EV/EBITDA against 13.4% operating margins and a 1.16x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependencies, sector correlations, or second-order bottlenecks beyond the stated sector (Health Care) and industry classification.

  • Key Question #1: Can IQV sustain or expand its 13.4% operating margin and 9.4% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $16.31B and free cash flow of $1.92B, how will capital allocation balance growth reinvestment against $13.88B in total debt?
  • Key Question #3: How sensitive is IQV's 31.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.16x)?

IQV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IQVIA Holdings Inc. (IQV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IQV Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IQV Bull vs. Bear Conversation Board — What's Your Call at $258.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IQV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IQV:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $350.20 (+31.0%)
📌 Pinned Debate

Institutional accumulation and options positioning earn the top RQD pillar score of 18 of 20, while a GREEN-flagged catalyst cites a Q3

Don't sleep on IQV's setup in Health Care. Institutional accumulation and options positioning earn the top RQD pillar score of 18 of 20, while a GREEN-flagged catalyst cites a Q3 beat driven by R&D Solutions.. Beta of 1.16 means it moves fast when momentum turns, and the 5-pillar RQD gauge (61/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — IQV's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $205.84 (-23.0%)
Spot @ $267.33

Debt/Equity of 2.14 and reported debt rising from $5.83B to $13.88B, with a Forensic Balance Sheet score of 10 of 20 and a P/E TTM

I respect the product at IQVIA Holdings Inc., but the stock at $267.33 is a different story. Debt/Equity of 2.14 and reported debt rising from $5.83B to $13.88B, with a Forensic Balance Sheet score of 10 of 20 and a P/E TTM of 33.3, leave limited margin for error.. FCF yield is 4.24% and RQD sits at 61/100 (C-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%